Abstract

Interleukin-22 (IL-22) is a critical immune defence cytokine that maintains intestinal homeostasis and promotes wound healing and tissue regeneration, which can support the growth of colorectal tumours. Mutations in the adenomatous polyposis coli gene (Apc) are a major driver of familial colorectal cancers (CRCs). How IL-22 contributes to APC-mediated tumorigenesis is poorly understood. To investigate IL-22 signalling in wild-type (WT) and APC-mutant cells, we performed RNA sequencing (RNAseq) of IL-22–treated murine small intestinal epithelial organoids. In WT epithelia, antimicrobial defence and cellular stress response pathways were most strongly induced by IL-22. Surprisingly, although IL-22 activates signal transducer and activator of transcription 3 (STAT3) in APC-mutant cells, STAT3 target genes were not induced. Our analyses revealed that ApcMin/Min cells are resistant to IL-22 due to reduced expression of the IL-22 receptor, and increased expression of inhibitors of STAT3, particularly histone deacetylases (HDACs). We further show that IL-22 increases DNA damage and genomic instability, which can accelerate cellular transition from heterozygosity (ApcMin/+) to homozygosity (ApcMin/Min) to drive tumour formation. Our data reveal an unexpected role for IL-22 in promoting early tumorigenesis while excluding a function for IL-22 in transformed epithelial cells.

Highlights

  • Chronic inflammation is positively associated with intestinal tumorigenesis [1,2]

  • Our analyses revealed that ApcMin/multiple intestinal neoplasia (Min) cells are resistant to IL-22 due to reduced expression of the IL-22 receptor, and increased expression of inhibitors of signal transducer and activator of transcription 3 (STAT3), histone deacetylases (HDACs)

  • IL-22 binds to the IL-22 receptor, which is composed of two heterodimeric subunits, the interleukin 22 receptor subunit alpha 1 (IL22RA1) and the interleukin 10 receptor 2 (IL-10R2) [10,11]

Read more

Summary

Introduction

Chronic inflammation is positively associated with intestinal tumorigenesis [1,2]. Recent data have implicated the cytokine Interleukin-22 (IL-22) in colorectal cancers (CRCs). IL-22 producing cells are enriched in human CRC and associated with its development [3,4,5]. IL-22 is produced by type 3 innate lymphoid cells (ILCs), CD4+ and CD8+ T cells, and γδ T cells during intestinal inflammation [4,6,7,8,9]. IL-22 binds to the IL-22 receptor, which is composed of two heterodimeric subunits, the interleukin 22 receptor subunit alpha 1 (IL22RA1) and the interleukin 10 receptor 2 (IL-10R2) [10,11].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call